[{"address1": "2505 Meridian Parkway", "address2": "Suite 100", "city": "Durham", "state": "NC", "zip": "27713", "country": "United States", "phone": "919 806 1074", "fax": "919 806 1146", "website": "https://www.chimerix.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael T. Andriole M.B.A.", "age": 51, "title": "CEO, President & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 820004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Alrutz J.D., Ph.D.", "age": 54, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 571941, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Allen S. Melemed M.B.A., M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 665498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  LaSpaluto", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas J. Riga", "age": 48, "title": "Chief Operating & Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Jakeman CPA", "age": 46, "title": "Vice President of Accounting & Finance", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joshua E. Allen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roy W. Ware M.B.A., Ph.D.", "title": "Chief Manufacturing Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.48, "open": 3.51, "dayLow": 3.2103, "dayHigh": 3.69, "regularMarketPreviousClose": 3.48, "regularMarketOpen": 3.51, "regularMarketDayLow": 3.2103, "regularMarketDayHigh": 3.69, "beta": 1.128, "forwardPE": -3.0678732, "volume": 1238546, "regularMarketVolume": 1238546, "averageVolume": 4017759, "averageVolume10days": 1768460, "averageDailyVolume10Day": 1768460, "bid": 3.37, "ask": 3.44, "bidSize": 500, "askSize": 900, "marketCap": 305009824, "fiftyTwoWeekLow": 0.75, "fiftyTwoWeekHigh": 3.69, "priceToSalesTrailing12Months": 1918.3008, "fiftyDayAverage": 1.5574, "twoHundredDayAverage": 1.08105, "currency": "USD", "enterpriseValue": 177391472, "floatShares": 75056133, "sharesOutstanding": 89973400, "sharesShort": 3439284, "sharesShortPriorMonth": 710246, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.0382, "heldPercentInsiders": 0.06628, "heldPercentInstitutions": 0.45648998, "shortRatio": 0.34, "shortPercentOfFloat": 0.0404, "impliedSharesOutstanding": 89973400, "bookValue": 1.51, "priceToBook": 2.2450333, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -83594000, "trailingEps": -0.94, "forwardEps": -1.03, "enterpriseToRevenue": 1115.67, "enterpriseToEbitda": -1.913, "52WeekChange": 2.625, "SandP52WeekChange": 0.25443196, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CMRX", "underlyingSymbol": "CMRX", "shortName": "Chimerix, Inc.", "longName": "Chimerix, Inc.", "firstTradeDateEpochUtc": 1365687000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7389e162-7c43-3cdb-be64-0bc435a74d1a", "messageBoardId": "finmb_3280635", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.39, "targetHighPrice": 11.0, "targetLowPrice": 6.0, "targetMeanPrice": 8.4, "targetMedianPrice": 8.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 136230000, "totalCashPerShare": 1.515, "ebitda": -92735000, "totalDebt": 644000, "quickRatio": 6.131, "currentRatio": 6.334, "totalRevenue": 159000, "debtToEquity": 0.474, "revenuePerShare": 0.002, "returnOnAssets": -0.3022, "returnOnEquity": -0.48589, "freeCashflow": -40054624, "operatingCashflow": -70297000, "revenueGrowth": 1.364, "operatingMargins": -953.57697, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]